Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies

Uffe Klausen*, Staffan Holmberg, Morten Orebo Holmström, Nicolai Grønne Dahlager Jørgensen, Jacob Handlos Grauslund, Inge Marie Svane, Mads Hald Andersen

*Corresponding author for this work

    Research output: Contribution to journalJournal articleResearchpeer-review

    250 Downloads (Pure)


    Peptides vaccination is an interesting approach to activate T-cells toward desired antigens in hematological malignancies. In addition to classical tumor associated antigens, such as cancer testis antigens, new potential targets for peptide vaccination comprise neo-antigens including JAK2 and CALR mutations, and antigens from immune regulatory proteins in the tumor microenvironment such as programmed death 1 ligands (PD-L1 and PD-L2). Immunosuppressive defenses of tumors are an important challenge to overcome and the T cell suppressive ligands PD-L1 and PD-L2 are often present in tumor microenvironments. Thus, PD-L1 and PD-L2 are interesting targets for peptide vaccines in diseases where the tumor microenvironment is known to play an essential role such as multiple myeloma and follicular lymphoma. In myelodysplastic syndromes the drug azacitidine re-exposes tumor associated antigens, why vaccination with related peptides would be an interesting addition. In myeloproliferative neoplasms the JAK2 and CALR mutations has proven to be immunogenic neo-antigens and thus possible targets for peptide vaccination. In this mini review we summarize the basis for these novel approaches, which has led to the initiation of clinical trials with various peptide vaccines in myelodysplastic syndromes, myeloproliferative neoplasms, multiple myeloma, and follicular lymphoma.
    Original languageEnglish
    Article number2264
    JournalFrontiers in Immunology
    Number of pages8
    Publication statusPublished - 2018


    • Peptide vaccination
    • Follicular lymphoma
    • Multiple myeloma
    • Myeloproliferative neoplasms
    • Myelodysplastic syndrome
    • PD-1
    • Cancer testis antigen
    • Neo-antigens


    Dive into the research topics of 'Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies'. Together they form a unique fingerprint.

    Cite this